Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report) today and set a price target of $56.00. The company’s shares closed last Friday at $46.03.
Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crinetics Pharmaceuticals, and CymaBay Therapeutics. According to TipRanks, Rahimi has an average return of 12.6% and a 42.66% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Crinetics Pharmaceuticals with a $50.92 average price target, representing a 10.62% upside. In a report released on February 29, Robert W. Baird also assigned a Buy rating to the stock with a $52.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $47.48 and a one-year low of $15.23. Currently, Crinetics Pharmaceuticals has an average volume of 821.1K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRNX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Crinetics Pharmaceuticals (CRNX) Company Description:
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing’s disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Read More on CRNX:
- Biotech Alert: Searches spiking for these stocks today
- Crinetics price target raised to $60 from $50 at JMP Securities
- Crinetics price target raised to $52 from $45 at Baird
- Crinetics reports Q4 EPS (90c) , consensus (86c)
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
